Compare VYX & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | AZTA |
|---|---|---|
| Founded | 1881 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Machinery/Components |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 1995 |
| Metric | VYX | AZTA |
|---|---|---|
| Price | $9.70 | $35.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $15.17 | ★ $43.60 |
| AVG Volume (30 Days) | ★ 2.7M | 631.1K |
| Earning Date | 11-06-2025 | 11-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,653,000,000.00 | $593,821,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $5.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.55 | $23.91 |
| 52 Week High | $15.34 | $55.64 |
| Indicator | VYX | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 35.43 | 59.68 |
| Support Level | $9.89 | $34.34 |
| Resistance Level | $10.36 | $38.20 |
| Average True Range (ATR) | 0.37 | 1.47 |
| MACD | 0.02 | 0.31 |
| Stochastic Oscillator | 8.00 | 66.33 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.